Sight Sciences (SGHT) – Analysts’ Recent Ratings Changes

Sight Sciences (NASDAQ: SGHT) recently received a number of ratings updates from brokerages and research firms:

• 1/5/2026 – Sight Sciences was given a new $9.00 price target on by analysts at Piper Sandler.
• 1/5/2026 – Sight Sciences was given a new $9.00 price target on by analysts at Raymond James Financial, Inc..
• 1/5/2026 – Sight Sciences was upgraded by analysts at Piper Sandler from a “neutral” rating to an “overweight” rating. They now have a $9.00 price target on the stock, up previously from $5.00.
• 12/29/2025 – Sight Sciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/23/2025 – Sight Sciences had its price target raised by analysts at UBS Group AG from $7.00 to $12.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Sight Sciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/11/2025 – Sight Sciences had its price target raised by analysts at Citigroup Inc. from $5.50 to $9.10. They now have a “neutral” rating on the stock.
• 12/8/2025 – Sight Sciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – Sight Sciences had its price target raised by analysts at Morgan Stanley from $6.00 to $8.00. They now have an “equal weight” rating on the stock.
• 11/26/2025 – Sight Sciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/20/2025 – Sight Sciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity at Sight Sciences

In other news, insider Jeremy B. Hayden sold 9,385 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $7.82, for a total transaction of $73,390.70. Following the sale, the insider directly owned 247,205 shares in the company, valued at $1,933,143.10. This represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CTO David Badawi sold 3,695 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $7.48, for a total transaction of $27,638.60. Following the completion of the sale, the chief technology officer directly owned 1,917,109 shares in the company, valued at approximately $14,339,975.32. The trade was a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 126,092 shares of company stock worth $970,005 in the last 90 days. 28.90% of the stock is owned by company insiders.

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.